JP2024105479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024105479A5 JP2024105479A5 JP2024076658A JP2024076658A JP2024105479A5 JP 2024105479 A5 JP2024105479 A5 JP 2024105479A5 JP 2024076658 A JP2024076658 A JP 2024076658A JP 2024076658 A JP2024076658 A JP 2024076658A JP 2024105479 A5 JP2024105479 A5 JP 2024105479A5
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- hematopoietic
- hematopoietic cell
- cells
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551075P | 2017-08-28 | 2017-08-28 | |
| US62/551,075 | 2017-08-28 | ||
| JP2020511435A JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
| PCT/US2018/048317 WO2019046285A1 (en) | 2017-08-28 | 2018-08-28 | CD33 EXON 2 DONOR STEM CELLS FOR USE WITH CD33 TARGETING AGENTS |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511435A Division JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024105479A JP2024105479A (ja) | 2024-08-06 |
| JP2024105479A5 true JP2024105479A5 (https=) | 2024-11-01 |
Family
ID=65525985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511435A Pending JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
| JP2024076658A Pending JP2024105479A (ja) | 2017-08-28 | 2024-05-09 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511435A Pending JP2020531535A (ja) | 2017-08-28 | 2018-08-28 | Ｃｄ３３標的剤と共に使用するためのｃｄ３３エクソン２欠損型ドナー幹細胞 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11718659B2 (https=) |
| EP (1) | EP3676372A4 (https=) |
| JP (2) | JP2020531535A (https=) |
| WO (1) | WO2019046285A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108290939B (zh) | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| MX2021008490A (es) * | 2019-01-16 | 2021-09-28 | Univ Columbia | Composiciones y metodos para la inhibicion de antigenos con especificidad de linaje. |
| CN114423865A (zh) * | 2019-05-23 | 2022-04-29 | Vor生物制药股份有限公司 | Cd33修饰的组合物和方法 |
| AU2020336211A1 (en) * | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CD123 modification |
| US20220290160A1 (en) | 2019-08-28 | 2022-09-15 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| CA3153700A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| WO2021081244A1 (en) * | 2019-10-22 | 2021-04-29 | Fred Hutchinson Cancer Research Center | Base editor-mediated cd33 reduction to selectively protect therapeutic cells |
| CN116157135A (zh) * | 2020-06-03 | 2023-05-23 | 纽约市哥伦比亚大学理事会 | 使用基于crispr的碱基编辑器系统抑制谱系特异性抗原的组合物和方法 |
| US20240110189A1 (en) | 2020-08-28 | 2024-04-04 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20240238344A1 (en) | 2020-08-28 | 2024-07-18 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| CA3199623A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| WO2022147347A1 (en) | 2020-12-31 | 2022-07-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| CN115443333B (zh) * | 2021-04-27 | 2025-04-25 | 上海驯鹿生物技术有限公司 | 一种基因编辑的造血干细胞及其与car-t细胞的联合应用 |
| EP4330394A2 (en) * | 2021-04-28 | 2024-03-06 | Eisai R&D Management Co., Ltd. | Antisense oligonucleotides and their use for treatment of neurodegenerative disorders |
| CA3236152A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| EP4598588A1 (en) * | 2022-10-05 | 2025-08-13 | Musc Foundation for Research Development | Superantigen vaccine conjugate for the treatment of cancer |
| WO2024168312A1 (en) * | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913765YA (en) * | 2014-07-21 | 2020-03-30 | Novartis Ag | Treatment of cancer using a cd33 chimeric antigen receptor |
| US10201606B2 (en) | 2014-11-26 | 2019-02-12 | Miltenyi Biotec Gmbh | Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases |
| CN108290939B (zh) * | 2015-10-16 | 2023-01-13 | 纽约市哥伦比亚大学理事会 | 用于抑制谱系特异性抗原的组合物和方法 |
| WO2017177011A1 (en) * | 2016-04-06 | 2017-10-12 | University Of Florida Research Foundataion, Inc. | Biomarkers for anti-leukemic therapy |
| SG11201907870VA (en) * | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| US11718659B2 (en) * | 2017-08-28 | 2023-08-08 | The Trustees Of Columbia University In The City Of New York | CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents |
-
2018
- 2018-08-28 US US16/640,086 patent/US11718659B2/en active Active
- 2018-08-28 EP EP18852123.1A patent/EP3676372A4/en active Pending
- 2018-08-28 JP JP2020511435A patent/JP2020531535A/ja active Pending
- 2018-08-28 WO PCT/US2018/048317 patent/WO2019046285A1/en not_active Ceased
-
2023
- 2023-06-06 US US18/206,269 patent/US20240166721A1/en not_active Abandoned
-
2024
- 2024-05-09 JP JP2024076658A patent/JP2024105479A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024105479A5 (https=) | ||
| Diorio et al. | Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks | |
| Yang et al. | Challenges and opportunities of allogeneic donor-derived CAR T cells | |
| JP2020531535A5 (https=) | ||
| AU2025205147A1 (en) | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies | |
| Clark et al. | Cultured human follicular dendritic cells. Growth characteristics and interactions with B lymphocytes | |
| Tomuleasa et al. | Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia | |
| Veuillen et al. | Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy | |
| US12398402B2 (en) | Reducing CD33 expression to selectively protect therapeutic cells | |
| EP3757133A1 (en) | Isolated chimeric antigen receptor, modified t cell comprising same and use thereof | |
| Oh et al. | Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia | |
| Kujawski et al. | Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation | |
| US20250041339A1 (en) | Engineered Pan-Leukocyte Antigen CD45 to Facilityate CAR T Cell Therapy | |
| US20220195441A1 (en) | Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias | |
| CN119095953A (zh) | 细胞表面受体的表位工程 | |
| US12295973B2 (en) | Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells | |
| US20240139321A1 (en) | Universal car-t cell targeting gd2, preparation method therefor, and application thereof | |
| JP2025510415A (ja) | 養子細胞療法用の遺伝的に操作された抗体抵抗性（ｇｅａｒ）細胞 | |
| JPWO2021247856A5 (https=) | ||
| CN118647709A (zh) | 效应细胞及其用于实体瘤中同种异体过继性细胞疗法的用途 | |
| Grier | Genome engineering to expand applications of human T-cell immunotherapy | |
| WO2022040277A1 (en) | Constitutively active tcf1 to promote memory-associated traits in car t cells | |
| Cubitt | Induced CD8α Identifies Enhanced Human NK Cell Il-15-Induced Proliferation and Metabolism and Modulates NK Cell Activation | |
| WO2025099197A1 (en) | Smad4 engineered cytotoxic lymphocytes for cell therapy | |
| WO2024173594A1 (en) | Modified stem cell compositions and methods for use |